
    
      This is a double-blind, placebo-controlled, crossover trial to evaluate the safety,
      tolerability and efficacy of inhaled ASM8 for the treatment of allergen-induced asthma.
      Individuals with stable, mild to moderate allergic asthma by American Thoracic Society (ATS)
      criteria (1), with a history of episodic wheeze and shortness of breath, will be eligible for
      enrolment. The study is divided into 2 parts.
    
  